Cost considerations of medical therapy for glaucoma

Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension

Lewis H. Silver · American Journal of Ophthalmology · 1998 · 191 citations

Medicine, Ophthalmology, Pharmacology +17

Latanoprost

Peter Watson · Ophthalmology · 1998 · 152 citations

A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide11Ms. Boyle, Dr. Ghosh, and Dr. Adamsons were employees of Merck & Co., Inc, the manufacturer of timolol and dorzolamide, at the time this study was conducted. COSOPT and TRUSOPT are trademark products of Merck & Co., Inc, Whitehouse Station, New Jersey. The other authors have no proprietary interest in timolol, dorzolamide, or Merck.

Janet E Boyle, Kalyan Ghosh, David K. Gieser et al. · Ophthalmology · 1998 · 150 citations

Medicine, Pharmacology, Pharmacotherapy +8

A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide 11Ms. Clineschmidt, Dr. Adamsons, Dr. Snyder, and Dr. Reines are employees of Merck & Co., Inc., the manufacturer of the dorzolamide-timolol combination. The other authors have no proprietary interest in the dorzolamide-timolol combination or in Merck.

Coleen M. Clineschmidt, Robert Williams, Ellen Snyder et al. · Ophthalmology · 1998 · 140 citations

Medicine, Pharmacology, Pharmacotherapy +5

Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension

Raymond P. LeBlanc · Ophthalmology · 1998 · 132 citations

Medicine, Ophthalmology, Pharmacology +8